Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. Idelalisib acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase. It was developed by Gilead Sciences. It is taken orally (swallowed by mouth).
Read the full article on WikipediaChronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) Clinical criteria: Treatment Phase: Initial treatment The condition must be confirmed Chronic lymphocytic leukaemia (CLL) prior to initiation of treatment; OR The condition must be confirmed Small lymphocytic lymphoma (SLL) prior to initiation of treatment, AND Patient must not have previously received PBS-subsidised treatment with this drug for this condition, AND The treatment must be in combination with rituximab for up to a maximum of 8 doses under this restriction, followed by monotherapy for this condition, AND The condition must have relapsed or be refractory to at least one prior therapy, AND The condition must be CD20 positive, AND The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition. Treatment criteria: Must be treated by a medical practitioner.
Refractory follicular B-cell non-Hodgkin's lymphoma Clinical criteria: Treatment Phase: Initial treatment The condition must be refractory to a prior therapy with rituximab within 6 months after completion of treatment with rituximab, AND The condition must be refractory to a prior therapy with an alkylating agent within 6 months after completion of treatment with an alkylating agent, AND The treatment must be the sole PBS-subsidised therapy for this condition. The condition is considered refractory to a prior therapy when the patient experiences less than a partial response or progression of disease within 6 months after completion of the prior therapy. The condition is considered refractory to both rituximab and an alkylating agent if the agents were administered together or in successive treatment regimens. The date of completion of prior therapies with rituximab and an alkylating agent must be documented in the patient's medical records.
“PI3Kδ is expressed in normal and malignant B-cells. By inhibiting it, idelalisib induces apoptosis and prevents proliferation in cell lines derived from malignant B-cells and in primary tumor cells. It also inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5 signaling, which are involved in the trafficking and homing of B-cells to the lymph nodes and bone marrow.”
“8.2 hours”
Working under the parallel aged-care framework? Aged-care equivalent →